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Prescribed minimum benefits or
minimum prescribed benefits?
To the Editor: Discovery Health notes the contents of Professor
Rayner’s submission to the SAMJ.1
If we had had the opportunity to reply before publication, we
would have been able to confirm that the medication prescribed
for the patient mentioned in the article was approved within our
appeals process on 5 July 2004, before publication of the SAMJ.
We take umbrage that we were not afforded the opportunity to
address and comment on Professor Rayner’s concerns before
publication. It is unfortunate that we have had to write this letter
retrospectively, especially as it may not reach the
readership/audience of the August 2004 journal.
In relation to this article, allow us to clarify further.
1. Discovery Health has always been fully compliant with the
legal requirements of Act 101 and its requirements. In point of
fact, during 2003 Discovery Health was an integral partner in
assisting the Council for Medical Schemes in drafting treatment
algorithms. The regulations permitted the creation of formularies
related to the Chronic Disease List (CDL) conditions, in order that
this benefit could be included in lower premium plans,
promoting affordability and thus allowing more people to access
cover.
2. With specific reference to hypertension, the drug formulary
that we offered was fully compliant with the Council’s guidelines
and requirements and was also in accordance with the most
recent Hypertension Guideline update. The formulary applied to
specific benefit options, and was not a general feature of all
options.
3. Members who purchased an ancillary benefit have access to
an enhanced chronic benefit and are not limited to a formulary.
Those who do have the ancillary benefit qualify for basic chronic
cover as stipulated by the Prescribed Minimum Benefits. The
choice of drugs included within the formulary on these plans
was based on their cost effectiveness, related either to their list
price or to the discount price offered to Discovery Health
members.
For drugs prescribed outside of the formulary, the scheme
allows members to fund their therapy with a monthly medical
allowance set at a similar level to that of items included in the
formulary.
Since legislation has now been implemented with regard to
single exit prices and the discontinuation of mark-ups related to
drugs, Discovery Health can now afford to expand its formulary,
enabling members to access as many drugs as is clinically
appropriate and cost-effective to the Scheme.
As regulations also require consideration of other drugs not
on the formulary for ‘ineffective’ care and for ‘adverse effects’, an
appeal process was created to facilitate this. It is important to
note that this is not an open ‘loophole’ to bypass the formulary,
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Chloroquine-induced retinal toxicity
To the Editor: Dr Rivett’s letter on chloroquine-induced retinal
toxicity1 requires comment.
For Dr Rivett to state that ‘many patients develop profound
visual loss every year as a result of chloroquine toxicity’ is
misleading.  We comment on three aspects: 
1. Data referring to choloroquine alone are scant, as many
authors deal with antimalarials as a group. MacKenzie2 was
probably the first to examine the issue after it became accepted
that retinopathy had been identified as a potential problem. He
quotes data clearly establishing a dose-related effect. Of 928
patients treated with between 2.0 and 3.7 mg/kg/d of
chloroquine ‘for years’, none developed retinopathy. The
incidence of pigmentary degeneration without scotoma or visual
loss increased to 6% at doses above 4.6 mg/kg/d.  At doses
estimated to range from 11 to 33 mg/kg/d, chloroquine is
associated with a sharply rising incidence of scotomas and
decreasing visual acuity. Despite these findings there are widely
quoted figures for visual loss in the literature, ranging from
0.001% to 40%.3 Easterbrook,4 a leading ophthalmologist,
concludes that ‘the incidence of retinopathy is very low at doses
of less than 6.5 mg/kg/day of hydroxychloroqine or less than 3.0
mg/kg/day chloroquine . . .’, and this probably sums up our
current state of knowledge on this subject.  
This matter has received considerable attention in the
dermatology and rheumatology literature, and we would
assume that  most of our colleagues follow the published
guidelines (as published in Dr Rivett’s  letter.)
2. Chloroquine  appears  to be a more effective drug than
hydroxychloroquine.5 Removing the drug from the market and
replacing it with one that is less potent only risks exposing our
patients to potentially more toxic alternatives.                                    
3. While both hydroxychloroquine and chloroquine induce
retinal damage, it is generally accepted that the former is less
toxic. The general opinion is that patients on either drug require
monitoring. The debate at the moment is the most cost effective
manner to achieve this.4
It is unfortunate that the contents of Dr Rivett’s letter were
reported in a local paper,  which could only have generated
anxiety in any patient taking this generally very safe drug. 
Dave Whitelaw
Rheumatology Unit 
Tygerberg Hospital
Tygerberg, W Cape
Sue Jessop
Division of Dermatology
Groote Schuur Hospital
Cape Town
1. Rivett K. Chloroquine-induced retinal toxicity (Scientific letter). S Afr Med J 2004; 94: 41.
2.  McKenzie AH. An appraisal of chloroquine. Arthr Rheum 1970; 13: 280-287.
3.  Easterbrook  M.  Ocular effects and safety of antimalarial agents. Am J Med 1988; 85: suppl 4A,
23-29.
4. Easterbrook M. Screening for antimalarial toxicity: current concepts. Can J Ophthalmol 2002; 37:
325-328.
5.  Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second line drugs
in rheumatoid arthritis. Arthr Rheum 1990; 33: 1449-1461.
